scholarly journals Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China

2020 ◽  
Vol Volume 12 ◽  
pp. 8935-8941
Author(s):  
Kai Ding ◽  
Hong Yu ◽  
Yuan-Yuan Shao ◽  
Li-Yan Li ◽  
Chao-Meng Wang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Efficacy And Safety ◽  
Single Center ◽  
Real World Data ◽  
World Data ◽  
Single Center Study ◽  
Center Study

Efficacy and Safety of Sesame Oral Immunotherapy—A Real-World, Single-Center Study

2019 ◽  
Vol 7 (8) ◽  
pp. 2775-2781.e2 ◽  
Author(s):  
Liat Nachshon ◽  
Michael R. Goldberg ◽  
Michael B. Levy ◽  
Michael Y. Appel ◽  
Naama Epstein-Rigbi ◽  
...  
Keyword(s):  
Real World ◽  
Oral Immunotherapy ◽  
Efficacy And Safety ◽  
Single Center ◽  
Single Center Study ◽  
Center Study

scholarly journals PS1415 SURVIVAL OF MULTIPLE MYELOMA PATIENTS DIAGNOSED 1970–2015: REAL-WORLD DATA FROM A SINGLE CENTER

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 650-651
Author(s):  
L.G. Rodríguez-Lobato ◽  
A. Pereira ◽  
C. Fernández de Larrea ◽  
N. Tovar ◽  
M.T. Cibeira ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Single Center ◽  
Real World Data ◽  
World Data

Real World Data on the Efficacy and Safety of Ixazomib Based Therapy in Multiple Myeloma: An Observational Study from China

2019 ◽  
Vol 19 (10) ◽  
pp. e265
Author(s):  
Jing Li ◽  
Jingli Zhuang ◽  
Zheng Wei ◽  
Liji Ji ◽  
Zhixiang Cheng ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Observational Study ◽  
Real World ◽  
Efficacy And Safety ◽  
Real World Data ◽  
World Data

scholarly journals Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

2019 ◽  
Vol 110 (5) ◽  
pp. 559-565 ◽  
Author(s):  
Szilvia Lovas ◽  
Gergely Varga ◽  
Péter Farkas ◽  
Tamás Masszi ◽  
Nikolett Wohner ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Efficacy And Safety ◽  
Real World Data ◽  
World Data ◽  
Refractory Multiple Myeloma

scholarly journals Efficacy and Safety of Venetoclax Combinations in t(11;14) Multiple Myeloma: Real World Data Collected from 7 Hungarian Centers

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 32-33
Author(s):  
Virág Réka Szita ◽  
Gábor Mikala ◽  
János Fábián ◽  
Péter Rajnics ◽  
László Rejtő ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Residual Disease ◽  
Progression Free Survival ◽  
Serum Levels ◽  
Al Amyloidosis ◽  
Efficacy And Safety ◽  
Real World Data ◽  
World Data ◽  
Off Label

Background. Myeloma patients reaped immense benefit from the introduction of new classes of drugs over the last decades. This improvement, however, was much less marked in patients with translocation 11;14 [t(11;14)], a group in which immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) - the two most important pillars of current myeloma care - are less effective. This subgroup of patients used to be known for their relatively slow pace of progression often experiencing long plateau phases following autologous stem cell transplantation (ASCT), whereas at the same time t(11;14) is also disproportionately prevalent in difficult to treat clinical entities such as plasma cell leukemia or AL amyloidosis. Venetoclax, a selective bcl-2 inhibitor first approved for CLL was investigated for the treatment of relapsed myeloma patients and although it failed to show benefit for myeloma patients as a whole, t(11;14) patients showed exceptional responses, thus paving the way towards the first genetically targeted treatment in myeloma. As a result, its off label use is on the rise, even though clinicians have to face unanswered questions regarding the right dosage and therapy length, as well as the potential for adverse events (AEs), especially infections. Real world data could help elucidate its optimal use, but is as of yet very limited. Aims and methods. We addressed all Hungarian centers treating myeloma to evaluate the efficacy and safety of venetoclax, collecting data about the treatment duration, AEs, dose modifications and treatment discontinuations, and analysed response rates as well as progression free survival (PFS). Results. 33 patients were reported from 7 Hungarian sites. After the initial analyses, we identified two distinct rationales for venetoclax treatment. 22 patients were relapsed and heavily pretreated with an average of 4.5 prior lines; here venetoclax was chosen as ultimum refugium. In this group, combination partners were bortezomib-dexamethasone (VelDex) in 14 patients, 5 had dexamethasone only, one VRd, one DRd and one Kd. Considering the highly pretreated nature of this group, the overall response rate was a remarkably high 95% with 40.9% partial, 31.8% very good partial, and 22.7% complete responses. Treatment mostly continued until progression. The median PFS and OS calculated from venetoclax initiation were 299 and 437 days. The most common AEs were cytopenias and infections reported in 8 and 6 patients with 1 fatal infection. In the second group, 11 patients received venetoclax after a suboptimal initial response (6 PR, 4 SD, 1 PD) to their first line IMiD+PI combination with the goal of further tumor elimination preceding ASCT. Remarkably, although the length of venetoclax treatment was short - median 2 cycles -, all 11 patients deepened their response to at least VGPR and 7 to CR. 9 patients had ASCT converting 2 further VGPRs into CR, so at the end of the planned protocol 10 of the 11 patients had CR. Venetoclax was combined with VelDex in 9 and VTD in 2 cases, the one year PFS and OS were 91 and 100%, with no venetoclax related AEs reported. An important aspect of our analysis was the question of venetoclax dosing, as the appropriate dose in this indication is not yet clear. Reflecting this uncertainty, as well as funding difficulties with this off-label drug, only one patient received 800 mg dose as seen in the Bellini trial; one received 600 mg daily, with all others taking 400 mg or less. To counteract this lower daily dose available, some centers employed a combination with clarithromycin, a strong CYP3A inhibitor known to increase venetoclax serum levels two- to threefold. Where available, serum venetoclax levels were monitored to ensure serum levels comparable to regular dosing. Another point to emphasize is that 5 patients in the relapsed, and another 2 in the frontline group had deletion 17p, usually resulting in refractoriness to standard treatments. Among these patients however, 5 reached VGPR, 1 PR, and only one progressed on venetoclax treatment. Some responses proved lasting especially in the frontline group. Conclusion. Our results highlight the importance of targeted treatments in multiple myeloma. We experienced lasting responses in quadruple-refractory patients. In the newly diagnosed group where the depth of pre-ASCT response has a big impact on PFS, venetoclax may have a role converting suboptimal responses into CRs by eliminating residual disease. Figure Disclosures Illés: Takeda, Seattle Genetics: Research Funding; Novartis, Janssen, Pfizer, Roche;: Other: Travel, Accommodations, Expenses; Celgene, Janssen, Novartis,Roche, Takeda: Consultancy; Janssen, Celgene, Takeda, Novartis Pharma SAS, Pfizer Pharmaceuticals Israel, Roche;: Consultancy, Honoraria. OffLabel Disclosure: venetoclax use in t(11;14) myeloma which is not yet licensed

scholarly journals Conventional single-chamber pacemakers versus transcatheter pacing systems in a “real world” cohort of patients: A comparative prospective single-center study

2021 ◽  
Author(s):  
Jose Luis Martinez-Sande ◽  
Javier Garcia-Seara ◽  
Laila Gonzalez-Melchor ◽  
Moises Rodriguez-Mañero ◽  
Aurora Baluja ◽  
...  
Keyword(s):  
Real World ◽  
Single Center ◽  
Single Chamber ◽  
Single Center Study ◽  
Center Study

scholarly journals Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tae-Hwan Kim ◽  
Hun Do Cho ◽  
Yong Won Choi ◽  
Hyun Woo Lee ◽  
Seok Yun Kang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Real World ◽  
Group Performance ◽  
Eastern Cooperative Oncology Group ◽  
Conversion Surgery ◽  
Single Center ◽  
Her2 Positive ◽  
Real World Data ◽  
World Data ◽  
The Real

Abstract Background Since the results of the ToGA trial were published, trastuzumab-based chemotherapy has been used as the standard first-line treatment for HER2-positive recurrent or primary metastatic gastric cancer (RPMGC). However, the real-world data has been rarely reported. Therefore, we investigated the outcomes of trastuzumab-based chemotherapy in a single center. Methods This study analyzed the real-world data of 47 patients with HER2-positive RPMGC treated with trastuzumab-based chemotherapy in a single institution. Results With the median follow-up duration of 18.8 months in survivors, the median overall survival (OS) and progression-free survival were 12.8 and 6.9 months, respectively, and the overall response rate was 64%. Eastern Cooperative Oncology Group performance status 2 and massive amount of ascites were independent poor prognostic factors for OS, while surgical resection before or after chemotherapy was associated with favorable OS, in multivariate analysis. In addition, 5 patients who underwent conversion surgery after chemotherapy demonstrated an encouraging median OS of 30.8 months, all with R0 resection. Conclusions Trastuzumab-based chemotherapy in patients with HER2-positive RPMGC in the real world demonstrated outcomes almost comparable to those of the ToGA trial. Moreover, conversion surgery can be actively considered in fit patients with a favorable response after trastuzumab-based chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document